Background: Few studies have assessed the effect of prothrombotic blood abnormalities on the risk of deep vein thrombosis (DVT) with hormone replacement therapy (HRT).
Methods: We studied postmenopausal women with suspected DVT in whom HRT use and prothrombotic blood abnormalities were sought. Cases had unprovoked DVT and controls had no DVT and without DVT risk factors. The risk of DVT was determined in women with and without prothrombotic abnormalities.
Results: A total of 510 postmenopausal women with suspected DVT were assessed; 57 cases and 283 controls were identified. Compared to HRT, nonusers without the factor V Leiden mutation, the risk of DVT was increased in estrogen-progestin HRT users (odds ratio [OR], 3.2; 95% confidence interval [CI]: 1.2-8.6) and in nonusers with the factor V Leiden mutation (OR, 5.3; 1.9-15.4) and appears multiplied in users of estrogen-progestin HRT with the factor V Leiden mutation (OR, 17.1; 3.7-78). Compared to HRT, nonusers with normal factor VIII, the risk of DVT was increased in estrogen-progestin HRT users with normal factor VIII (OR, 2.8; 1.0-7.9) and in HRT nonusers with the highest factor VIII quartile (OR, 6.0; 2.1-17), and appears to be multiplied in women who are users of estrogen-progestin HRT with the highest factor VIII quartile (OR, 17.0; 3.6-80).
Conclusions: In postmenopausal women who are estrogen-progestin HRT users, the presence of the factor V Leiden mutation or an elevated factor VIII level appears to have a multiplicative effect on their overall risk of DVT, increasing it 17-fold compared to women without these blood abnormalities who are HRT nonusers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1076029610387587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Menopausal hormone therapy and risk of venous thromboembolism: The story so far.
Afr J Reprod Health
March 2024
Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Malaysia.
Menopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence.
View Article and Find Full Text PDFAssociation of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis.
Sci Rep
July 2022
Department of Global Health Policy, Graduate School of Medicine, The University of 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Article Synopsis
- Hormone replacement therapy (HRT) is commonly used for relieving menopausal symptoms, but its link to gastric cancer was unclear until this study.
- Researchers conducted a systematic review and meta-analysis, analyzing 11 studies that included over 1.9 million women, which found that HRT use was associated with a 28% reduced risk of gastric cancer compared to non-users.
- The findings suggested a consistent reduction in gastric cancer risk for both estrogen-only and estrogen-progestin therapies, highlighting the need for future research to explore the mechanisms behind this association.
Starting age of oestrogen-progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index.
Clin Endocrinol (Oxf)
July 2021
Department of Gastroenterology, Nutrition, and Endocrinology, Osaka Women's and Children's Hospital, Izumi, Japan.
Objective: Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, particularly during young adulthood.
Design: A retrospective study from three tertiary care hospitals in Japan.
Patients: One hundred and three patients with TS aged between 18 and 30 years of age who underwent dual-energy X-ray absorptiometry.
Translational implications of the interactions between hormones and age-related hearing loss.
Hear Res
March 2021
Dept. Medical Engineering, Global Center for Hearing & Speech Research, University of South Florida, Tampa FL, USA.
Provocative research has revealed both positive and negative effects of hormones on hearing as we age; with in some cases, mis-regulation of hormonal levels in instances of medical comorbidities linked to aging, lying at the heart of the problem. Animal model studies have discovered that hormonal fluctuations can sharpen hearing for improved communication and processing of mating calls during reproductive seasons. Sex hormones sometimes have positive effects on auditory processing, as is often the case with estrogen, whereas combinations of estrogen and progesterone, and testosterone, can have negative effects on hearing abilities, particularly in aging subjects.
View Article and Find Full Text PDFThe Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature.
Medicina (Kaunas)
August 2019
Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), S. Orsola Hospital, University of Bologna, Via Massarenti, 13-40138 Bologna, Italy.
: Hormonal replacement therapy (HRT) is effective in treating many debilitating symptoms of menopause. However, its use in women with uterine fibroids is widely debated, based on the susceptibility of these tumors to sexual steroids. This review aims to ascertain the effects of HRT on leiomyomas development and growth in postmenopausal women.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!